Table 2.
Proportional hazards model for the development of hepatocellular carcinoma
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Factors | Hazards ratio (range†) | p | Hazards ratio (range†) | p |
| Age (years) | 1.0 (0.99-1.1) | 0.12 | ||
| Sex (1: male) | 5.6 (1.6-19) | 0.0062 | 5.5 (1.5-21) | 0.011 |
| Body mass index | 1.2 (1.0-1.3) | 0.0086 | 1.2 (1.0-1.3) | 0.029 |
| Liver fibrosis | 3.8 (1.9-7.3) | <0.0001 | ||
| Hepatitis activity | 1.1 (0.44-2.6) | 0.88 | ||
| Liver steatosis (>30%) | 2.1 (0.95-4.8) | 0.067 | ||
| rs 8099917 of IL28B (TT) | 0.62 (0.25-1.6) | 0.31 | ||
| rs 738409 of PNPLA3 (148 M) | 0.40 (0.17-0.97) | 0.043 | ||
| Amino acid 70 of HCV core (glutamine) | 3.4 (0.86-14) | 0.082 | ||
| Alanine aminotransferase (>40 IU/L) | 1.2 (0.68-2.2) | 0.51 | ||
| Platelet count (104/mm3) | 0.77 (0.69-0.87) | <0.0001 | 0.76 (0.66-0.88) | 0.0002 |
| Alpha fetoprotein (ng/mL) | 1.1 (1.0-1.1) | 0.0002 | 1.1 (1.0-1.1) | 0.046 |
| HOMA-IR | 0.97 (0.79-1.2) | 0.76 | ||
| Sustained virological response | 0.13 (0.03-0.57) | 0.0067 | ||
| Null or partial virological response | 2.4 (1.0-5.9) | 0.048 | ||
†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.